These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26805075)

  • 1. [Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
    Yokoo H; Kamiyama T; Kakisaka T; Orimo T; Wakayama K; Shimada S; Tsuruga Y; Kamachi H; Taketomi A
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1497-9. PubMed ID: 26805075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
    Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.
    Huan HB; Lau WY; Xia F; Ma KS; Bie P
    World J Gastroenterol; 2014 Oct; 20(39):14505-9. PubMed ID: 25339839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
    Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
    World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
    Yoshimoto T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Takasu C; Ishikawa D; Teraoku H; Bando Y; Shimada M
    Anticancer Res; 2018 Jan; 38(1):501-507. PubMed ID: 29277815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
    Park JG
    Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
    Barbier L; Fuks D; Pessaux P; Muscari F; Le Treut YP; Faivre S; Belghiti J
    Ann Surg Oncol; 2013 Oct; 20(11):3603-9. PubMed ID: 23715965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
    Kitajima T; Hatano E; Mitsunori Y; Taura K; Fujimoto Y; Mizumoto M; Okajima H; Kaido T; Minamiguchi S; Uemoto S
    Clin J Gastroenterol; 2015 Oct; 8(5):300-5. PubMed ID: 26249525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
    Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
    Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
    Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report.
    Lee HY; Yang KH; Choi BH; Park YM; Yoon KT; Ryu JH; Chu CW
    Transplant Proc; 2016; 48(1):247-50. PubMed ID: 26915876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
    Nakamura K; Beppu T; Hayashi H; Okabe H; Imai K; Nitta H; Chikamoto A; Ishiko T; Sasaki M; Baba H
    Int Surg; 2015 May; 100(5):908-14. PubMed ID: 26011214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
    Kim Y; Hosoda Y; Kakita N; Yamada Y; Yamasaki M; Nishino M; Okano M; Nagai K; Yasui M; Tsujinaka T
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2124-6. PubMed ID: 25731444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
    Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
    Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.
    Tanaka K; Shimada M; Kudo M
    Oncology; 2014; 87 Suppl 1():104-9. PubMed ID: 25427741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.